Presently, the main development in the search for anti-SLE drugs which target IFN pathways involves targeting type I IFNs, including employing monoclonal antibodies against IFN-α or its receptor IFNAR, or the use of a therapeutic vaccine to induce polyclonal anti-IFN-α neutralizing antibodies. This evidence concerns the gene IFNA2 and systemic lupus erythematosus.